Perjeta
Perjeta (chemical name: pertuzumab) is approved by the U.S. Food and Drug Administration to be used in combination with Herceptin (chemical name: trastuzumab), another targeted therapy medicine, and Taxotere (chemical name: docetaxel), a type of chemotherapy, to treat HER2-positive, metastatic breast cancer that hasn’t been treated with either Herceptin or chemotherapy yet. (Perjeta was called Omnitarg in earlier studies.)
In this section you can learn more about:
